Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (137) 137
index medicus (137) 137
oncology (83) 83
melanoma (73) 73
female (72) 72
male (67) 67
middle aged (59) 59
aged (55) 55
dermatology (49) 49
adult (46) 46
melanoma - drug therapy (43) 43
cancer (42) 42
skin neoplasms - pathology (39) 39
melanoma - pathology (36) 36
metastasis (35) 35
skin neoplasms - drug therapy (35) 35
care and treatment (31) 31
ipilimumab (30) 30
skin (30) 30
aged, 80 and over (28) 28
survival (28) 28
metastatic melanoma (27) 27
skin cancer (26) 26
treatment outcome (26) 26
antineoplastic agents - therapeutic use (25) 25
analysis (24) 24
immunology (23) 23
prognosis (23) 23
retrospective studies (23) 23
melanoma - genetics (22) 22
mutation (22) 22
tumors (22) 22
histamine (20) 20
immunotherapy (20) 20
melanoma - mortality (20) 20
melanoma - secondary (20) 20
nivolumab (20) 20
metastases (19) 19
patients (19) 19
abridged index medicus (18) 18
medical colleges (17) 17
neoplasm staging (17) 17
hematology, oncology and palliative medicine (16) 16
clinical trials (15) 15
malignant-melanoma (15) 15
pembrolizumab (15) 15
skin neoplasms - mortality (15) 15
skin neoplasms - therapy (15) 15
therapy (15) 15
young adult (15) 15
antineoplastic agents - adverse effects (14) 14
disease-free survival (14) 14
lymphatic metastasis (14) 14
open-label (14) 14
proto-oncogene proteins b-raf - antagonists & inhibitors (14) 14
receptors, histamine h4 (14) 14
skin neoplasms - genetics (14) 14
dendritic cells (13) 13
diagnosis (13) 13
kaplan-meier estimate (13) 13
medical research (13) 13
melanoma - therapy (13) 13
vemurafenib (13) 13
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
atopic-dermatitis (12) 12
cutaneous melanoma (12) 12
expression (12) 12
h-4 receptor (12) 12
mutations (12) 12
proto-oncogene proteins b-raf - genetics (12) 12
survival rate (12) 12
animals (11) 11
antibodies, monoclonal - adverse effects (11) 11
cell biology (11) 11
chemotherapy (11) 11
dendritic cells - immunology (11) 11
drug therapy (11) 11
neoplasm metastasis (11) 11
sentinel lymph node biopsy (11) 11
antibodies, monoclonal - therapeutic use (10) 10
antineoplastic agents - administration & dosage (10) 10
management (10) 10
medicine, research & experimental (10) 10
safety (10) 10
allergy (9) 9
braf (9) 9
cell lung-cancer (9) 9
cells, cultured (9) 9
complications and side effects (9) 9
dabrafenib (9) 9
follow-up studies (9) 9
lymph nodes - pathology (9) 9
medicine & public health (9) 9
mice (9) 9
protein kinase inhibitors - therapeutic use (9) 9
psoriasis (9) 9
radiotherapy (9) 9
receptors, histamine - metabolism (9) 9
sentinel lymph node (9) 9
untreated melanoma (9) 9
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Die entwicklung der therapie des hautkrebses geht weiter – Bericht von der Jahrestagung der American society of clinical oncology (ASCO) in Chicago vom 31.5– 3.6. 2018
by Gutzmer, Ralf
JDDG - Journal of the German Society of Dermatology, ISSN 1610-0379, 08/2018, Volume 16, Issue 8, pp. 1063 - 1064
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Die Entwicklung der Therapie des Hautkrebses geht weiter – Bericht von der Jahrestagung der American Society of Clinical Oncology (ASCO) in Chicago vom 31.5.– 3.6. 2018
by Gutzmer, Ralf
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 08/2018, Volume 16, Issue 8, pp. 1063 - 1064
Trade and professional associations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Die Entwicklung der Therapie des Hautkrebses geht weiter - Bericht von der Jahrestagung der American Society of Clinical Oncology (ASCO) in Chicago vom 31.5.- 3.6. 2018
: Forum - ADO
by Gutzmer, Ralf
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 08/2018, Volume 16, Issue 8, pp. 1063 - 1064
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Dabrafenib in BRAF -mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
by Hauschild, Axel, Prof and Grob, Jean-Jacques, Prof and Demidov, Lev V, Prof and Jouary, Thomas, MD and Gutzmer, Ralf, MD and Millward, Michael, MD and Rutkowski, Piotr, PhD and Blank, Christian U, PhD and Miller, Wilson H, PhD and Kaempgen, Eckhart, PhD and Martín-Algarra, Salvador, PhD and Karaszewska, Boguslawa, MD and Mauch, Cornelia, Prof and Chiarion-Sileni, Vanna, MD and Martin, Anne-Marie, PhD and Swann, Suzanne, PhD and Haney, Patricia, BSN and Mirakhur, Beloo, PhD and Guckert, Mary E, MSN and Goodman, Vicki, MD and Chapman, Paul B, MD
Lancet, The, ISSN 0140-6736, 2012, Volume 380, Issue 9839, pp. 358 - 365
Summary Background Dabrafenib, an inhibitor of mutated BRAF, has clinical activity with a manageable safety profile in studies of phase 1 and 2 in patients... 
Internal Medicine | SURVIVAL | MEDICINE, GENERAL & INTERNAL | INHIBITION | SOLID TUMORS | RESISTANCE | CANCER | VEMURAFENIB | Dacarbazine - therapeutic use | Humans | Middle Aged | Oximes - therapeutic use | Male | Treatment Outcome | Antineoplastic Agents, Alkylating - therapeutic use | Young Adult | Disease-Free Survival | Melanoma - genetics | Melanoma - drug therapy | Aged, 80 and over | Adult | Female | Aged | Imidazoles - therapeutic use | Mutation | Proto-Oncogene Proteins B-raf | Antimitotic agents | Usage | Patient outcomes | Melanoma | Research | Antineoplastic agents | Drug therapy | Meetings | Human immunodeficiency virus--HIV | Committees | Clinical trials | Acute coronary syndromes | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
by Weber, Jeffrey S, Dr and D'Angelo, Sandra P, MD and Minor, David, MD and Hodi, F Stephen, MD and Gutzmer, Ralf, MD and Neyns, Bart, MD and Hoeller, Christoph, MD and Khushalani, Nikhil I, MD and Miller, Wilson H, MD and Lao, Christopher D, MD and Linette, Gerald P, MD and Thomas, Luc, MD and Lorigan, Paul, FRCP and Grossmann, Kenneth F, MD and Hassel, Jessica C, MD and Maio, Michele, MD and Sznol, Mario, MD and Ascierto, Paolo A, MD and Mohr, Peter, MD and Chmielowski, Bartosz, MD and Bryce, Alan, MD and Svane, Inge M, MD and Grob, Jean-Jacques, MD and Krackhardt, Angela M, MD and Horak, Christine, PhD and Lambert, Alexandre, PhD and Yang, Arvin S, MD and Larkin, James, FRCP
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 4, pp. 375 - 384
Summary Background Nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, can result in durable responses in patients with melanoma who have... 
Hematology, Oncology and Palliative Medicine | ANTI-PD-1 ANTIBODY | RESPONSE CRITERIA | ONCOLOGY | SAFETY | TOLERANCE | LYMPHOMA | BLOCKADE | PD-1 | CANCER | EXPRESSION | IPILIMUMAB | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carboplatin - administration & dosage | Male | Melanoma - pathology | CTLA-4 Antigen - immunology | Drug-Related Side Effects and Adverse Reactions - pathology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Melanoma - genetics | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Aged, 80 and over | Adult | Female | Aged | CTLA-4 Antigen - therapeutic use | Neoplasm Staging | Paclitaxel - administration & dosage | Medical colleges | Care and treatment | Chemotherapy | Immunotherapy | Immunoglobulin G | Melanoma | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Aktueller Stand zu BRAF- und MEK-Inhibitoren in der Behandlung des malignen Melanoms
by Gutzmer, Ralf
JDDG, ISSN 1610-0379, 05/2015, Volume 13, Issue 5, p. 485
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Aktueller Stand zu BRAF- und MEK-Inhibitoren in der Behandlung des malignen Melanoms
: Forum - ADO
by Gutzmer, Ralf
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 05/2015, Volume 13, Issue 5, pp. 485 - 487
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Aktueller Stand zu BRAF‐ und MEK‐Inhibitoren in der Behandlung des malignen Melanoms
by Gutzmer, Ralf
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 05/2015, Volume 13, Issue 5, pp. 485 - 487
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
by Migden, Michael R, Dr and Guminski, Alexander, PhD and Gutzmer, Ralf, Prof and Dirix, Luc, MD and Lewis, Karl D, MD and Combemale, Patrick, MD and Herd, Robert M, MD and Kudchadkar, Ragini, MD and Trefzer, Uwe, Prof and Gogov, Sven, MD and Pallaud, Celine, PhD and Yi, Tingting, PhD and Mone, Manisha, PhD and Kaatz, Martin, MD and Loquai, Carmen, MD and Stratigos, Alexander J, Prof and Schulze, Hans-Joachim, MD and Plummer, Ruth, Prof and Chang, Anne Lynn S, MD and Cornélis, Frank, MD and Lear, John T, MD and Sellami, Dalila, MD and Dummer, Reinhard, Prof
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 6, pp. 716 - 728
Summary Background Patients with advanced basal cell carcinoma have limited treatment options. Hedgehog pathway signalling is aberrantly activated in around... 
Hematology, Oncology and Palliative Medicine | VISMODEGIB | SOLID TUMORS | ONCOLOGY | RESISTANCE | OPEN-LABEL | QUALITY-OF-LIFE | EUROPEAN-ORGANIZATION | MUTATIONS | HEDGEHOG-PATHWAY | Neoplasm Recurrence, Local - radiotherapy | Skin Neoplasms - drug therapy | Skin Neoplasms - radiotherapy | Humans | Middle Aged | Biphenyl Compounds - adverse effects | Neoplasm Recurrence, Local - drug therapy | Male | Neoplasm Recurrence, Local - surgery | Neoplasm Recurrence, Local - pathology | Neoplasm Metastasis | Pyridines - adverse effects | Aged, 80 and over | Adult | Female | Skin Neoplasms - surgery | Skin Neoplasms - pathology | Carcinoma, Basal Cell - radiotherapy | Pyridines - administration & dosage | Double-Blind Method | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Basal Cell - pathology | Disease-Free Survival | Carcinoma, Basal Cell - surgery | Biphenyl Compounds - administration & dosage | Carcinoma, Basal Cell - drug therapy | Aged | Medical colleges | Care and treatment | Basal cell carcinoma | Surgical clinics | Clinical trials | Skin | Metastasis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
by Dummer, Reinhard, Prof and Schadendorf, Dirk, Prof and Ascierto, Paolo A, MD and Arance, Ana, MD and Dutriaux, Caroline, MD and Di Giacomo, Anna Maria, MD and Rutkowski, Piotr, Prof and Del Vecchio, Michele, MD and Gutzmer, Ralf, Prof and Mandala, Mario, MD and Thomas, Luc, Prof and Demidov, Lev, Prof and Garbe, Claus, Prof and Hogg, David, MD and Liszkay, Gabriella, Prof and Queirolo, Paola, MD and Wasserman, Ernesto, MD and Ford, James, MS and Weill, Marine, MSc and Sirulnik, L Andres, MD and Jehl, Valentine, MSc and Bozón, Viviana, MD and Long, Georgina V, Prof and Flaherty, Keith, MD
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 4, pp. 435 - 445
Summary Background There are no established therapies specific for NRAS -mutant melanoma despite the emergence of immunotherapy. We aimed to assess the... 
Hematology, Oncology and Palliative Medicine | DABRAFENIB | MEK INHIBITION | ONCOLOGY | IMPROVED SURVIVAL | SELUMETINIB | BRAF | MUTATIONS | DOCETAXEL | VEMURAFENIB | Dacarbazine - administration & dosage | Prognosis | Follow-Up Studies | Membrane Proteins - genetics | Humans | Middle Aged | Male | Survival Rate | Melanoma - pathology | Mutation - genetics | Benzimidazoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | GTP Phosphohydrolases - genetics | Melanoma - genetics | Melanoma - drug therapy | Aged, 80 and over | Adult | Female | Aged | Neoplasm Staging | Medical colleges | Care and treatment | Hospitals | Sarcoma | Immunotherapy | Melanoma | Skin | Research institutes | Analysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
by Ascierto, Paolo A, Dr and Del Vecchio, Michele, MD and Robert, Caroline, Prof and Mackiewicz, Andrzej, Prof and Chiarion-Sileni, Vanna, MD and Arance, Ana, MD and Lebbé, Céleste, Prof and Bastholt, Lars, MD and Hamid, Omid, MD and Rutkowski, Piotr, Prof and McNeil, Catriona, MD and Garbe, Claus, Prof and Loquai, Carmen, MD and Dreno, Brigitte, Prof and Thomas, Luc, Prof and Grob, Jean-Jacques, Prof and Liszkay, Gabriella, Prof and Nyakas, Marta, MD and Gutzmer, Ralf, Prof and Pikiel, Joanna, MD and Grange, Florent, MD and Hoeller, Christoph, MD and Ferraresi, Virginia, MD and Smylie, Michael, MD and Schadendorf, Dirk, Prof and Mortier, Laurent, Prof and Svane, Inge Marie, MD and Hennicken, Delphine, MSc and Qureshi, Anila, MD and Maio, Michele, MD
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 611 - 622
Summary Background A phase 2 trial suggested increased overall survival and increased incidence of treatment-related grade 3–4 adverse events with ipilimumab... 
Hematology, Oncology and Palliative Medicine | UNTREATED MELANOMA | SURVIVAL | PLUS DACARBAZINE | PEMBROLIZUMAB | ONCOLOGY | SCORES | POOLED ANALYSIS | CANCER-IMMUNOTHERAPY | NIVOLUMAB | Double-Blind Method | Follow-Up Studies | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Survival Rate | Treatment Outcome | Alanine Transaminase - blood | Antineoplastic Agents - administration & dosage | Diarrhea - chemically induced | Melanoma - secondary | Hypophysitis - chemically induced | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - adverse effects | Colitis - chemically induced | Melanoma - drug therapy | Intention to Treat Analysis | Female | Aged | Clinical trials | Complications and side effects | Medical colleges | Care and treatment | Metastasis | Melanoma | Index Medicus | Life Sciences | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF -mutant metastatic melanoma: a phase 2 double-blind randomised study
by Robert, Caroline, Dr and Dummer, Reinhard, Prof and Gutzmer, Ralf, Prof and Lorigan, Paul, MB and Kim, Kevin B, MD and Nyakas, Marta, MD and Arance, Ana, MD and Liszkay, Gabriella, Prof and Schadendorf, Dirk, Prof and Cantarini, Mireille, MBChB and Spencer, Stuart, MSc and Middleton, Mark R, Prof
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 733 - 740
Summary Background Patients with metastatic melanoma, 50% of whose tumours harbour a BRAF mutation, have a poor prognosis. Selumetinib, a MEK1/2 inhibitor, has... 
Hematology, Oncology and Palliative Medicine | CELL LUNG-CANCER | TRIAL | KINASE KINASE-1/2 INHIBITOR | MULTICENTER | ONCOLOGY | ORAL MEK INHIBITOR | IMPROVED SURVIVAL | INHIBITOR AZD6244 ARRY-142886 | OPEN-LABEL | MUTATIONS | VEMURAFENIB | Dacarbazine - adverse effects | Skin Neoplasms - drug therapy | Humans | Middle Aged | Male | Antineoplastic Agents, Alkylating - administration & dosage | Skin Neoplasms - enzymology | Benzimidazoles - administration & dosage | Time Factors | DNA Mutational Analysis | Brazil | Proto-Oncogene Proteins B-raf - metabolism | Dacarbazine - administration & dosage | Genetic Predisposition to Disease | Neoplasms, Unknown Primary - genetics | Europe | Logistic Models | Antineoplastic Agents, Alkylating - therapeutic use | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Mutation | Antineoplastic Agents, Alkylating - adverse effects | Melanoma - mortality | Dacarbazine - therapeutic use | United States | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Melanoma - enzymology | Neoplasms, Unknown Primary - enzymology | Melanoma - genetics | Skin Neoplasms - mortality | Adult | Female | Skin Neoplasms - pathology | Neoplasms, Unknown Primary - drug therapy | Double-Blind Method | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Neoplasms, Unknown Primary - mortality | Melanoma - secondary | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Aged | Neoplasms, Unknown Primary - pathology | Care and treatment | Chemotherapy | Gene mutations | Analysis | Melanoma | Metastasis | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Raw Materials for Future Energy Supply
by Wellmer, Friedrich W and Buchholz, Peter and Gutzmer, Jens and Hagelüken, Christian and Herzig, Peter and Littke, Ralf and Thauer, Rudolf K
01/2019, 1st ed. 2019, ISBN 3319912283, 248
This is the first book that analyses the future raw materials supply from the demand side of a society that chiefly relies on renewable energies, which is of... 
Power resources | Energy Materials | Earth Sciences | Biogeosciences | Economic Geology | Renewable and Green Energy
eBook
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text The development of the treatment of melanoma continues - Reports from the annual conferences of the ESMO and the SMR in October/November 2016
by Gutzmer, Ralf and Höller, Christoph
JDDG - Journal of the German Society of Dermatology, ISSN 1610-0379, 03/2017, Volume 15, Issue 3, pp. 350 - 352
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text The histamine H4 receptor is functionally expressed on TH2 cells
by Gutzmer, Ralf and Mommert, Susanne and Gschwandtner, Maria and Zwingmann, Katja and Stark, Holger and Werfel, Thomas
Journal of Allergy and Clinical Immunology, ISSN 0091-6749, 03/2009, Volume 123, Issue 3, pp. 619 - 625
Background: Histamine influences T-cell reactions via histamine receptors 1 and 2. The histamine receptor 4 (H R) is the most recently identified histamine... 
H | Histamine | receptor | T cells | IL-31 | Studies | Proteins | Signal transduction | Lymphocytes | Ligands | Regulation | Blood banks | Dermatitis | Experiments | Allergies | Chemokines | Immune system
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
by Eggermont, Alexander M.M and Blank, Christian U and Mandala, Mario and Long, Georgina V and Atkinson, Victoria and Dalle, Stéphane and Haydon, Andrew and Lichinitser, Mikhail and Khattak, Adnan and Carlino, Matteo S and Sandhu, Shahneen and Larkin, James and Puig, Susana and Ascierto, Paolo A and Rutkowski, Piotr and Schadendorf, Dirk and Koornstra, Rutger and Hernandez-Aya, Leonel and Maio, Michele and van den Eertwegh, Alfonsus J.M and Grob, Jean-Jacques and Gutzmer, Ralf and Jamal, Rahima and Lorigan, Paul and Ibrahim, Nageatte and Marreaud, Sandrine and van Akkooi, Alexander C.J and Suciu, Stefan and Robert, Caroline
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 19, pp. 1789 - 1801
A blinded trial involving patients with resected stage III melanoma showed that adjuvant pembrolizumab every 3 weeks for a year was associated with a 1-year... 
HIGH-RISK MELANOMA | SURVIVAL | MEDICINE, GENERAL & INTERNAL | ANTI-PD-1 THERAPY | EORTC 18952 | TUMOR BURDEN | CUTANEOUS MELANOMA | PHASE-3 TRIAL | PEGYLATED INTERFERON-ALPHA-2B | NODE-POSITIVE MELANOMA | IPILIMUMAB | Skin Neoplasms - drug therapy | Humans | Middle Aged | Male | Adjuvants, Immunologic - adverse effects | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Adjuvants, Immunologic - therapeutic use | Skin Neoplasms - surgery | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Survival Rate | Disease-Free Survival | B7-H1 Antigen - antagonists & inhibitors | Melanoma - drug therapy | Intention to Treat Analysis | Quality of Life | Aged | B7-H1 Antigen - analysis | Infusions, Intravenous | Melanoma - surgery | Neoplasm Staging | Melanoma - mortality | Diagnosis | Drug therapy | Patients | Health aspects | Melanoma | Medical research | Lymphatic system | Risk groups | PD-1 protein | Committees | Metastasis | Survival | Skin cancer | Pembrolizumab | Hospitals | Motivation | PD-L1 protein | Myositis | Death | Mutation | Tumors | Cancer | Index Medicus | Abridged Index Medicus | Placebos | Placebos (Medicine) | Adjuvant treatment of cancer | Tractament adjuvant del càncer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
by Dummer, Reinhard and Ascierto, Paolo A and Gogas, Helen J and Arance, Ana and Mandala, Mario and Liszkay, Gabriella and Garbe, Claus and Schadendorf, Dirk and Krajsova, Ivana and Gutzmer, Ralf and Chiarion-Sileni, Vanna and Dutriaux, Caroline and de Groot, Jan Willem B and Yamazaki, Naoya and Loquai, Carmen and Moutouh-de Parseval, Laure A and Pickard, Michael D and Sandor, Victor and Robert, Caroline and Flaherty, Keith T
The Lancet Oncology, ISSN 1470-2045, 05/2018, Volume 19, Issue 5, pp. 603 - 615
Combined BRAF-MEK inhibitor therapy is the standard of care for -mutant advanced melanoma. We investigated encorafenib, a BRAF inhibitor with unique... 
DABRAFENIB | MEK INHIBITION | EFFICACY | ONCOLOGY | SAFETY | TRAMETINIB | MUTATED METASTATIC MELANOMA | DOUBLE-BLIND | COBIMETINIB | IMPROVED SURVIVAL | MUTATIONS | Skin Neoplasms - drug therapy | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Carbamates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Young Adult | Vemurafenib - administration & dosage | Benzimidazoles - administration & dosage | Time Factors | Melanoma - genetics | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Vemurafenib - adverse effects | Benzimidazoles - adverse effects | Skin Neoplasms - pathology | Melanoma - pathology | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Progression-Free Survival | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Biomarkers, Tumor - genetics | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Care and treatment | Analysis | Melanoma | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights